Earnings summaries and quarterly performance for CONMED.
Executive leadership at CONMED.
PB
Patrick Beyer
Detailed
President and Chief Executive Officer
CEO
AM
Andrew Moller
Detailed
Vice President, Corporate Controller
BL
Brent Lalomia
Detailed
Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations
EC
Edward Clifford
Detailed
Vice President, Global Manufacturing
HF
Hollie Foust
Detailed
Executive Vice President, General Counsel and Corporate Secretary
JF
John Ferrell
Detailed
Executive Vice President, Human Resources
JP
Johonna Pelletier
Detailed
Treasurer and Vice President, Tax
PS
Peter Shagory
Detailed
Executive Vice President, Strategy and Corporate Development
RG
Richard Glaze
Detailed
Chief Information Officer
SE
Stephan Epinette
Detailed
Vice President and General Manager, International
TG
Todd Garner
Detailed
Executive Vice President, Finance and Chief Financial Officer
Board of directors at CONMED.
Research analysts who have asked questions during CONMED earnings calls.
YL
Young Li
Jefferies
3 questions for CNMD
Also covers: ALC, ARAY, ATEC +8 more
FW
Frederick Wise
Stifel
2 questions for CNMD
Also covers: AORT, ATRC, AVNS +13 more
Michael Matson
Needham & Company
2 questions for CNMD
Also covers: AORT, ATRC, ENOV +22 more
RM
Robbie Marcus
JPMorgan Chase & Co.
2 questions for CNMD
Also covers: ABT, BAX, BDX +9 more
RM
Robert Marcus
JPMorgan Chase & Co.
2 questions for CNMD
Also covers: ABT, BAX, BDX +21 more
Travis Steed
Bank of America
2 questions for CNMD
Also covers: ABT, AXNX, BAX +19 more
KS
Kristen Stewart
CL King & Associates
1 question for CNMD
Also covers: AVNS, HAE, IART +3 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for CNMD
Also covers: APYX, ATEC, ATRC +18 more
Mike Matson
Needham & Company, LLC
1 question for CNMD
Also covers: ENOV, ESTA, HAE +16 more
PD
Phillip Dantoin
Piper Sandler
1 question for CNMD
Also covers: ATEC, FNA, PODD +2 more
VC
Vik Chopra
Wells Fargo & Company
1 question for CNMD
Also covers: ALGN, ATEC, ENOV +7 more
VC
Vikramjeet Chopra
Wells Fargo & Company
1 question for CNMD
Also covers: ALGN, ATEC, ENOV +9 more
Recent press releases and 8-K filings for CNMD.
CMR Surgical Secures FDA 510(k) Clearance for Versius Plus System
CNMD
Product Launch
New Projects/Investments
- CMR Surgical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versius Plus robotic surgical system for cholecystectomy procedures.
- This regulatory approval paves the way for the upcoming US commercial launch of the second-generation system in 2026.
- The Versius Plus system, characterized by its flexible, modular design and data-driven digital ecosystem, builds upon the first-generation Versius Surgical System, which received De Novo marketing authorization in October 2024.
- Outside the U.S., CMR Surgical's robotic surgical platforms have already completed over 40,000 surgical procedures.
6 days ago
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
CNMD
M&A
Guidance Update
New Projects/Investments
- CONMED Corporation announced its intention to exit its gastroenterology product lines as part of a portfolio optimization strategy, concluding its distribution agreement with Gore for VIABIL® effective January 1, 2026.
- The gastroenterology product lines are expected to generate $90 million to $95 million in revenue in 2025 with gross margins of approximately 45%.
- The company anticipates EPS dilution of $0.45–$0.55 in 2026 but projects an improvement in its consolidated gross margin profile by approximately 80 basis points after the exit.
- CONMED is reaffirming its 2025 revenue guidance of $1.365–$1.372 billion and adjusted EPS guidance of $4.48–$4.53, expecting no material impact on 2025 financial results.
Dec 5, 2025, 1:09 PM
ConMed Reports Q3 2025 Earnings and Announces Capital Allocation Shift
CNMD
Earnings
Dividends
Share Buyback
Guidance Update
- ConMed reported Q3 2025 total sales of $338 million, representing 6.7% year-over-year growth as reported, and adjusted diluted earnings per share of $1.08, an increase of 2.9% compared to the prior year quarter.
- The company's Board authorized a new $150 million share repurchase program and suspended its dividend policy, transitioning to prioritize share repurchases with an expectation of at least $25 million annually.
- An ongoing comprehensive strategic review confirmed that ConMed's strongest growth opportunities lie in core markets such as minimally invasive robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair, with platforms like BioBrace, Buffalo Filter, and AirSeal being cornerstones for future investments.
- For Q4 2025, ConMed projects revenue between $363 million and $370 million and adjusted EPS between $1.30 and $1.35, leading to a full-year 2025 reported revenue guidance of $1.365 billion-$1.372 billion and adjusted EPS guidance of $4.48-$4.53.
Nov 5, 2025, 9:30 PM
CONMED Reports Q3 2025 Earnings and Updates 2025 Guidance
CNMD
Earnings
Guidance Update
Product Launch
- CONMED reported Q3 2025 revenue of $337.9 million, an increase of 6.7% year-over-year as reported, and adjusted diluted EPS of $1.08, up 2.9% from the prior year period.
- For the September 2025 year-to-date period, revenue reached $1,001.5 million, a 4.2% increase year-over-year, with adjusted diluted EPS at $3.17, an increase of 12.1%.
- The company updated its 2025 financial guidance, projecting reported revenue between $1,365 million and $1,372 million, and adjusted diluted EPS (including FX and tariff impact) between $4.48 and $4.53.
- CONMED achieved a 3.0x leverage ratio in Q3 2025, ahead of expectations, and launched its new rotator cuff repair solution, BioBrace RC, in July 2025.
Nov 5, 2025, 9:30 PM
CONMED Corporation Announces Third Quarter 2025 Financial Results and Updated Guidance
CNMD
Earnings
Guidance Update
Share Buyback
- CONMED Corporation reported sales of $337.9 million for the third quarter ended September 30, 2025, representing a 6.7% increase year-over-year as reported and 6.3% in constant currency.
- Diluted net earnings per share (GAAP) for Q3 2025 were $0.09, a decrease from $1.57 in Q3 2024, while adjusted diluted net earnings per share increased to $1.08 from $1.05 in the prior year period.
- The company updated its full-year 2025 guidance, now expecting reported revenue between $1.365 billion and $1.372 billion and adjusted diluted net earnings per share in the range of $4.48 to $4.53.
- Effective October 31, 2025, the Board of Directors authorized a $150.0 million share repurchase program and suspended the quarterly cash dividend, with plans to repurchase at least $25.0 million in shares annually beginning in 2026.
Nov 5, 2025, 9:15 PM
CONMED Corporation Announces Q3 2025 Financial Results and Updates 2025 Outlook
CNMD
Earnings
Guidance Update
Share Buyback
- CONMED Corporation reported third quarter 2025 sales of $337.9 million, an increase of 6.7% year-over-year, with diluted net earnings per share (GAAP) of $0.09 and adjusted diluted net earnings per share of $1.08.
- The company updated its full-year 2025 revenue guidance to between $1.365 billion and $1.372 billion and adjusted diluted net earnings per share to a range of $4.48 to $4.53.
- Subsequent to quarter end, the Board of Directors authorized a $150.0 million share repurchase program and suspended the quarterly cash dividend, with plans to repurchase at least $25.0 million in shares annually beginning in 2026.
Nov 5, 2025, 9:05 PM
Conavi Medical Announces Leadership Changes
CNMD
CFO Change
Management Change
Product Launch
- Conavi Medical has appointed Mark Quick as its new Chief Financial Officer.
- The current CFO, Stefano Picone, will transition to a Chief Strategy Officer role.
- These leadership changes are aligned with the company's planned U.S. commercial launch and expansion, following the submission of its next-generation Novasight Hybrid imaging system to the FDA for 510(k) clearance.
Nov 3, 2025, 12:00 PM
Conavi Medical Secures Funding from Ontario's Life Sciences Scale-Up Fund
CNMD
New Projects/Investments
Product Launch
- Conavi Medical Corp. has entered into an agreement with the Province of Ontario as part of the Life Sciences Scale-Up Fund (LSSUF).
- Under this agreement, Conavi is eligible to receive up to $2.5 million CAD.
- The funding will cover up to one-third of eligible project costs related to the commercial launch of the next-generation Novasight Hybrid™ system.
- The Novasight Hybrid™ system is a proprietary device that uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for comprehensive coronary artery imaging.
Oct 29, 2025, 11:00 AM
Conavi Medical Reports Fiscal Q3 2025 Results and Operational Milestones
CNMD
Earnings
Product Launch
New Projects/Investments
- Conavi Medical reported fiscal Q3 2025 financial results, including revenue of $63,000 and a net loss of $3.6 million (or $0.05 per common share) for the quarter ended June 30, 2025.
- The company completed a $20 million financing in April 2025, which strengthens its balance sheet and supports anticipated U.S. launch activities.
- The US FDA 510(k) submission for the next-generation Novasight system remains on track for calendar Q3 2025, positioning the company for an anticipated U.S. launch in the first half of calendar 2026.
- Conavi conducted successful validation testing of the Novasight Hybrid™ system with key opinion leaders in July 2025, confirming it meets customer specifications and is competitive with existing solutions.
Aug 29, 2025, 11:00 AM
CONMED Corporation Announces Second Quarter 2025 Financial Results and Updates Full-Year 2025 Outlook
CNMD
Earnings
Guidance Update
- CONMED Corporation reported sales of $342.3 million for the second quarter ended June 30, 2025, representing a 3.1% increase year-over-year.
- Diluted net earnings per share (GAAP) for Q2 2025 were $0.69, compared to $0.96 in Q2 2024, while adjusted diluted net earnings per share increased to $1.15 from $0.98 in the same period.
- The company updated its full-year 2025 reported revenue guidance to a range of $1.356 billion to $1.378 billion, an increase from the prior guidance range of $1.350 billion to $1.378 billion.
- Full-year 2025 adjusted diluted net earnings per share guidance was raised to a range of $4.40 to $4.55, up from the previous range of $4.31 to $4.46, with an estimated negative impact of approximately $0.09 from tariffs in the second half of 2025.
Jul 30, 2025, 12:00 AM
Quarterly earnings call transcripts for CONMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more